NGR019: Randomized Double-blind Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma (MPM)

Trial Profile

NGR019: Randomized Double-blind Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma (MPM)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs NGR-TNF (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Sponsors MolMed
  • Most Recent Events

    • 27 May 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 20 Dec 2013 Planned End Date changed from 1 Jun 2013 to 1 Dec 2014.
    • 20 Dec 2013 MoliMed has enrolled the first patient in Russia in this trial, according to a company media release. The study foresees the enrolment of 100 patients in Europe and Russia by the end of 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top